MAPK-ERK activation in kidney of male rats chronically fed ochratoxin A at a dose causing a significant incidence of renal carcinoma

Toxicol Appl Pharmacol. 2007 Oct 15;224(2):174-81. doi: 10.1016/j.taap.2007.06.014. Epub 2007 Jul 3.

Abstract

Kidney samples of male Fischer 344 (F-344) rats fed a carcinogenic dose of OTA over 7 days, 21 days and 12 months were analysed for various cell signalling proteins known to be potentially involved in chemical carcinogenicity. OTA was found to increase the phosphorylation of atypical-PKC. This was correlated with a selective downstream activation of the MAP-kinase extracellular regulated kinases isoforms 1 and 2 (ERK1/2) and of their substrates ELK1/2 and p90RSK. Moreover, analysis of effectors acting upstream of PKC indicated a possible mobilisation of the insulin-like growth factor-1 receptor (lGFr) and phosphoinositide-dependent kinase-1 (PDK1) system. An increased histone deacetylase (HDAC) enzymatic activity associated with enhanced HDAC3 protein expression was also observed. These findings are potentially relevant with respect to the understanding of OTA nephrocarcinogenicity. HDAC-induced gene silencing has previously been shown to play a role in tumour development. Furthermore, PKC and the MEK-ERK MAP-kinase pathways are known to play important roles in cell proliferation, cell survival, anti-apoptotic activity and renal cancer development.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3-Phosphoinositide-Dependent Protein Kinases
  • Animals
  • Blotting, Western
  • Carcinogens / administration & dosage
  • Carcinogens / toxicity*
  • Gene Expression Regulation / drug effects
  • Histone Deacetylases / metabolism
  • Kidney / metabolism
  • Kidney Neoplasms / chemically induced
  • Kidney Neoplasms / physiopathology
  • MAP Kinase Signaling System / drug effects
  • Male
  • Mitogen-Activated Protein Kinase 1 / drug effects*
  • Mitogen-Activated Protein Kinase 1 / metabolism
  • Mitogen-Activated Protein Kinase 3 / drug effects*
  • Mitogen-Activated Protein Kinase 3 / metabolism
  • Ochratoxins / administration & dosage
  • Ochratoxins / toxicity*
  • Phosphorylation
  • Protein Serine-Threonine Kinases / drug effects
  • Protein Serine-Threonine Kinases / metabolism
  • Rats
  • Rats, Inbred F344
  • Receptor, IGF Type 1 / drug effects
  • Receptor, IGF Type 1 / metabolism
  • Ribosomal Protein S6 Kinases, 90-kDa / drug effects
  • Ribosomal Protein S6 Kinases, 90-kDa / metabolism
  • Time Factors
  • ets-Domain Protein Elk-1 / drug effects
  • ets-Domain Protein Elk-1 / metabolism

Substances

  • Carcinogens
  • Elk1 protein, rat
  • Ochratoxins
  • ets-Domain Protein Elk-1
  • ochratoxin A
  • Receptor, IGF Type 1
  • 3-Phosphoinositide-Dependent Protein Kinases
  • Pdpk1 protein, rat
  • Protein Serine-Threonine Kinases
  • Ribosomal Protein S6 Kinases, 90-kDa
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • Histone Deacetylases
  • histone deacetylase 3